Home>>Lipids>> Prostaglandins>>11β-13,14-dihydro-15-keto Prostaglandin F2α

11β-13,14-dihydro-15-keto Prostaglandin F2α (Synonyms: 11β13,14dihydro15keto PGF2α, 11-epi-13,14-dihydro-15-keto PGF2α)

Catalog No.GC40577

11β-13,14-dihydro-15-keto Prostaglandin F2α (11β-13,14-dihydro-15-keto PGF2α) is a metabolite of Prostaglandin D2 (PGD2) in the 15-hydroxy PGDH pathway.

Products are for research use only. Not for human use. We do not sell to patients.

11β-13,14-dihydro-15-keto Prostaglandin F2α Chemical Structure

Cas No.: 107615-77-0

Size Price Stock Qty
50μg
$77.00
In stock
100μg
$147.00
In stock
500μg
$616.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

11β-13,14-dihydro-15-keto Prostaglandin F2α (11β-13,14-dihydro-15-keto PGF2α) is a metabolite of Prostaglandin D2 (PGD2) in the 15-hydroxy PGDH pathway. Infusion or inhalation of tritiated PGD2 in normal males results in the appearance of peak levels of both 11β-PGF2α, as the immediate product, and 11β-13,14-dihydro-15-keto PGF2α in the plasma within 10 minutes. Homogenates of human lung metabolize PGD2 first to 11β-PGF2α and then to 11β-15-keto-PGF2α in the presence of NAD+, but no 11β-13,14-dihydro-15-keto PGF2α. Guinea pig liver and kidney homogenates metabolize PGD2 to 11β-13,14-dihydro-15-keto PGF2α, via 11β-PGF2α, in the presence of NAD+ and NADP+.

Reviews

Review for 11β-13,14-dihydro-15-keto Prostaglandin F2α

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 11β-13,14-dihydro-15-keto Prostaglandin F2α

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.